Company Analysis
Sign in

Amphastar Pharmaceuticals, Inc. (AMPH)

Nasdaq: AMPH · Pharmaceutical Preparations · Rancho Cucamonga, CA · filing with the SEC since 2005
Full chart Alerts Compare
Grade6.5
◀ Past 7.8● Present 7.4▶ Future 4.1
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

40 patents granted to the 7 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Amphastar Pharmaceuticals, Inc.’s names, not what it holds today.

Patents granted
40
38 utility, 1 design, 1 reissue, 1976 to Dec 31, 2025
Granted in 2025
6
Against 1 in 2024 and 1 in 2023
Applications published
29
since 2001, to Dec 31, 2025
Names they are printed under
7
its own name, a subsidiary
By yearGrantedApplications published
'04'07'08'13'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals6
Biotechnology2
Measurement1
Medical technology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name7 counted
Amphastar Pharmaceuticals, Inc. its own name
US, as the owner printed on each patent
26 granted
1 published
Amphastar Pharmaceuticals, Inc. its own name
named as the applicant on its applications, in US
0 granted
22 published
International Medication Systems, Limited a subsidiary
US, as the owner printed on each patent
8 granted
0 published
AMPHASTAR NANJING PHARMACEUTICALS INC a subsidiary
CN, as the owner printed on each patent
3 granted
1 published
AMPHASTAR NANJING PHARMACEUTICALS INC. a subsidiary
named as the applicant on its applications, in CN
0 granted
4 published
Armstrong Pharmaceuticals Inc. a subsidiary
US, as the owner printed on each patent
3 granted
0 published
Armstrong Pharmaceuticals Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 30, 202512,508,229Method for preparing stable peptide formulationsPharmaceuticalsAmphastar Pharmaceuticals, Inc.
Dec 16, 202512,496,272Stable epinephrine suspension formulation for inhalation with HFO propellantPharmaceuticalsAmphastar Pharmaceuticals, Inc.
Aug 12, 202512,383,516Albuterol aerosol suspension formulation for oral inhalation with high amount of green propellant hydrofluoroolefin (HFO) and free of co-solventPharmaceuticalsAmphastar Pharmaceuticals, Inc.
Jul 29, 202512,370,241Nasal powder formulation for treatment of hypoglycemiaPharmaceuticalsAmphastar Pharmaceuticals, Inc.
Jun 10, 202512,325,732Pro-insulin aspart structure and method for preparing insulin aspartBiotechnologyAMPHASTAR NANJING PHARMACEUTICALS INC
Feb 18, 202512,226,456Nasal powder formulation for treatment of hypoglycemiaPharmaceuticalsAmphastar Pharmaceuticals, Inc.
Mar 26, 202411,938,089Medication delivery systems and methodsMedical technologyAmphastar Pharmaceuticals, Inc.
Aug 15, 202311,726,049Small angle x-ray scattering methods for characterizing the iron core of iron carbohydrate colloid drug productsMeasurementAmphastar Pharmaceuticals, Inc.
Dec 13, 202211,524,987Highly purified recombinant human insulin (RHI) API and methods of producing the sameBiotechnologyAmphastar Pharmaceuticals, Inc.
Sep 20, 202211,446,360High-purity inhalable particles of insulin and insulin analogues, and high-efficiency methods of manufacturing the samePharmaceuticalsAmphastar Pharmaceuticals, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Sep 19, 20242024/0307637Intranasal (IN) Delivery Device for Delivering a Medication SolutionPharmaceuticalsAmphastar Pharmaceuticals, Inc.
Sep 12, 20242024/0299294TARGETED DELIVERY OF EFFECTIVE THERAPEUTIC MEDICATIONS TO THE RESPIRATORY TRACTPharmaceuticalsAmphastar Pharmaceuticals, Inc.
Aug 22, 20242024/0277632Epinephrine Pharmaceutical Formulations for Intranasal DeliveryPharmaceuticalsAmphastar Pharmaceuticals, Inc.
Jul 11, 20242024/0225955MEDICATION DELIVERY SYSTEMS AND METHODSMedical technologyAmphastar Pharmaceuticals, Inc.
Sep 14, 20232023/0287077NOVEL PROINSULIN GLARGINE AND METHOD FOR PREPARING INSULIN GLARGINE THEREFROMBiotechnologyAMPHASTAR NANJING PHARMACEUTICALS INC.
Aug 31, 20232023/0271770Anti-Viral Pharmaceutical Formulations Administered Via Devices for Lung Targeted DeliveryHandlingAmphastar Pharmaceuticals, Inc.
Aug 17, 20232023/0256099Safe Use of Bile Acids and Their Salts as Enhancers for Nasal Delivery of PharmaceuticalsPharmaceuticalsAmphastar Pharmaceuticals, Inc.
Jun 15, 20232023/0181500Naloxone Pharmaceutical Formulations for Intranasal (IN) DeliveryPharmaceuticalsAmphastar Pharmaceuticals, Inc.
May 4, 20232023/0140033INJECTABLE EPINEPHRINE FORMULATIONS DEMONSTRATING ACTIVE PHARMACEUTICAL INGREDIENT (API) RETENTION OVER TIMEPharmaceuticalsAmphastar Pharmaceuticals, Inc.
May 4, 20232023/0137790STABLE INJECTABLE EPINEPHRINE FORMULATIONS INCLUDING A METAL-CHELATING AGENTPharmaceuticalsAmphastar Pharmaceuticals, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 3 · Medical technology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton AMPH · research, not advice